dioxolane guanosine

Known as: 4-(2-amino-4-oxopurin-9-yl)-1,3-dioxolane-2-methanol, DXG 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1995-2016
02419952016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
OBJECTIVE We evaluated the safety, tolerability and antiretroviral activity of beta-D-2,6-diaminopurine dioxolane (DAPD… (More)
Is this relevant?
2006
2006
PURPOSE In this study, we chose three of the flavonoids isorhamnetin-3-O-rutinoside(IRR) diosmetin-7-O-beta-D-xylopyranosyl-(1-6… (More)
Is this relevant?
2006
2006
In this study, we chose three of the flavonoids isorhamnetin-3-O-rutinoside(IRR) diosmetin-7-O-β-d-xylopyranosyl-(1-6)-β-d… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2005
2005
We describe the completion of the set of four benzo-fused expanded DNA (xDNA) nucleoside analogues. We previously reported the… (More)
Is this relevant?
2004
2004
Amdoxovir [(-)-beta-D-2,6-diaminopurine dioxolane, DAPD], the prodrug of dioxolane guanosine (DXG), is currently in Phase I/II… (More)
Is this relevant?
2003
2003
The frequency of human immunodeficiency virus, type 1 (HIV-1) mutations in response to antiviral therapy and resulting drug… (More)
Is this relevant?
2002
2002
To design combination strategies for chronic hepatitis B therapy, we evaluated in vitro the inhibitory activity of 4 nucleoside… (More)
Is this relevant?
2002
2002
Amdoxovir ([-]-beta-D-2,6-diaminopurine dioxolane [DAPD]) is a nucleoside reverse transcriptase inhibitor (NRTI) with activity… (More)
Is this relevant?
2002
2002
Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) resistance mutations K65R and M184V result in changes in… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 3
Is this relevant?
1999
1999
DXG and its prodrug DAPD have been demonstrated to be effective inhibitors of HIV-1 in various cells. The EC50s for DXG were 0… (More)
Is this relevant?